inclusion criteria: * male and female adult (≥18 years old) * subjects with early mild/moderate symptoms of covid-19\*, who start the treatment without waiting results of a nasopharyngeal swab\*\* \* influenza-like syndrome, (i.e. flu, cough, myalgias/arthralgias or other painful symptoms, fever, gastrointestinal symptoms), no dyspnea, spo2 \>94%, or asthenia,ageusia/dysgeusia, anosmia, or mews 0 to 3. \*\* nasopharyngeal swab should be performed soon after the onset of symptoms possibly related to sars-cov-2 * subjects without known comorbidities in their previous medical history * subjects with known comorbidities that bring them at high risk of covid-19 progression (heart disease, hypertension, asthma or lung disease, diabetes, chronic kidney disease, stroke or neurological problems, weakened immune system - e.g. receiving chemotherapy -, and self-reported obesity or body-mass index of at least 30 kg/sqm) * informed consent

inclusion criteria: * male and female adult (≥18 years old) * subjects with early mild/moderate symptoms of covid-19\*, who start the treatment without waiting results of a nasopharyngeal swab\*\* \* influenza-like syndrome, (i.e. flu, cough, myalgias/arthralgias or other painful symptoms, fever, gastrointestinal symptoms), no dyspnea, spo2 \>94%, or asthenia,ageusia/dysgeusia, anosmia, or mews 0 to 3. \*\* nasopharyngeal swab should be performed soon after the onset of symptoms possibly related to sars-cov-2 * subjects without known comorbidities in their previous medical history * subjects with known comorbidities that bring them at high risk of covid-19 progression (heart disease, hypertension, asthma or lung disease, diabetes, chronic kidney disease, stroke or neurological problems, weakened immune system - e.g. receiving chemotherapy -, and self-reported obesity or body-mass index of at least 30 kg/sqm) * informed consent

inclusion criteria: male and female adult (≥18 years old) subjects with early mild/moderate symptoms of covid-19*, who start the treatment without waiting results of a nasopharyngeal swab** * influenza-like syndrome, (i.e. flu, cough, myalgias/arthralgias or other painful symptoms, fever, gastrointestinal symptoms), no dyspnea, spo2 >94%, or asthenia,ageusia/dysgeusia, anosmia, or mews 0 to 3. ** nasopharyngeal swab should be performed soon after the onset of symptoms possibly related to sars-cov-2 subjects without known comorbidities in their previous medical history subjects with known comorbidities that bring them at high risk of covid-19 progression (heart disease, hypertension, asthma or lung disease, diabetes, chronic kidney disease, stroke or neurological problems, weakened immune system - e.g. receiving chemotherapy -, and self-reported obesity or body-mass index of at least 30 kg/sqm) informed consent

inclusion criteria: male and female adult (≥18 years old) subjects with early mild/moderate symptoms of covid-19*, who start the treatment without waiting results of a nasopharyngeal swab** * influenza-like syndrome, (i.e. flu, cough, myalgias/arthralgias or other painful symptoms, fever, gastrointestinal symptoms), no dyspnea, spo2 >94%, or asthenia,ageusia/dysgeusia, anosmia, or mews 0 to 3. ** nasopharyngeal swab should be performed soon after the onset of symptoms possibly related to sars-cov-2 subjects without known comorbidities in their previous medical history subjects with known comorbidities that bring them at high risk of covid-19 progression (heart disease, hypertension, asthma or lung disease, diabetes, chronic kidney disease, stroke or neurological problems, weakened immune system - e.g. receiving chemotherapy -, and self-reported obesity or body-mass index of at least 30 kg/sqm) informed consent